中国药物警戒 ›› 2026, Vol. 23 ›› Issue (8): 944-947.
DOI: 10.19803/j.1672-8629.20250774

• 安全与合理用药 • 上一篇    下一篇

西格列他钠片致皮疹1例分析

林利萍1,2, 陈燕3, 贾雪岭1,2,*   

  1. 1上海市第六人民医院海口骨科与糖尿病医院药学部,海南 海口 570311;
    2中南大学湘雅医学院附属海口医院,海口市人民医院药学部,海南 海口 570208;
    3上海市第六人民医院海口骨科与糖尿病医院内分泌科,海南 海口 570311
  • 收稿日期:2025-11-05 出版日期:2026-08-15 发布日期:2026-08-17
  • 通讯作者: *贾雪岭,女,本科,主任药师,临床药学。E-mail: 3452629843@qq.com
  • 作者简介:林利萍,女,本科,主管药师,临床药学。
  • 基金资助:
    上海市第六人民医院海口骨科与糖尿病医院院内课题（SC2025038）

One case of rash caused by chiglitazar sodium tablets

Lin Liping1,2, Chen Yan3, Jia Xueling1,2,*   

  1. 1Department of Pharmacy, Haikou Orthopaedics and Diabetes Hospital of Shanghai Sixth Hospital, Haikou Hainan 570311, China;
    2Department of Pharmacy, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, Haikou People’s Hospital, Haikou Hainan 570208, China;
    3Department of Endocrinology, Haikou Orthopaedics and Diabetes Hospital of Shanghai Sixth People’s Hospital, Haikou Hainan 570311, China
  • Received:2025-11-05 Online:2026-08-15 Published:2026-08-17

PDF (PC)

56

摘要： 目的 探讨西格列他钠片致皮疹的临床特点及潜在免疫机制,为该药安全使用提供参考。方法 分析1例西格列他钠片致皮疹的病例资料,结合Naranjo’s评估量表进行关联性评价,并回顾相关文献,梳理可能的免疫机制及治疗策略,提出用药建议。结果 患者服用西格列他钠片后当日出现皮疹,6 d内泛发全身,停药48 h内症状消退。Naranjo’s评估量表评分为6分,提示药物关联性为“很可能”。文献显示该类皮疹可能与免疫机制相关。处置以停药为主,对症治疗后预后良好。结论 西格列他钠片具有诱发皮疹的风险,临床应加强用药监测与早期识别,一旦发生应及时停药并干预,以保障用药安全。

关键词: 西格列他钠片, 过氧化物酶体增长因子活化受体（PPAR）全激动剂, 2型糖尿病, 皮疹, 药品不良反应

Abstract: Objective To investigate the clinical characteristics and potential immunologic mechanisms associated with rashes induced by chiglitazar sodium tablets in order to provide a reference for safe medication. Methods The clinical data of a patient who had developed a rash following the administration of chiglitazar sodium was retrospectively analyzed. Causality was evaluated using the Naranjo Adverse Drug Reaction Probability Scale, and related literature was reviewed to explore possible immune mechanisms and treatment strategies. Results The patient presented with a rash the day chiglitazar sodium tablets were administrated, which progressed to a generalized rash across the body within six days. Symptoms were resolved within 48 hours of drug discontinuation. The Naranjo score was 6, indicating a “probable” association with the drug. Literature suggested that this type of rash might be linked to immune mechanisms. Treatment involved drug discontinuation, and the prognosis was favorable following symptomatic management. Conclusion Chiglitazar sodium tablets carry the risk of inducing rashes, so enhanced clinical monitoring and early identification are recommended. Upon the onset of a rash, immediate discontinuation of the drug and prompt intervention are essential to safe medication.

Key words: Chiglitazar Sodium Tablets, Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, Type 2 Diabetes, Rash, Adverse Drug Reaction

中图分类号: